[Clinical comprehensive evaluation of Shexiang Tongxin Dropping Pills].

Zhongguo Zhong Yao Za Zhi

International Research Center for Medicinal Administration, Peking University Beijing 100191, China.

Published: February 2024

Based on literature and questionnaire research, related evidence and related data on Shexiang Tongxin Dropping Pills were collected in terms of safety, effectiveness, economy, innovation, suitability, and accessibility. In addition, multi-criteria decision analysis(MCDA) model was used to comprehensively evaluate the clinical value of Shexiang Tongxin Dropping Pills. Quality control was carried out strictly based on evidence-based medicine evaluation. Shexiang Tongxin Dropping Pills were recommended for stable fatigue angina of coronary heart disease with Qi deficiency and blood stasis by guidelines and experts. The conventional treatment of western medicine adds Shexiang Tongxin Dropping Pills to reduce the frequency of angina attacks, shorten the duration, improve exercise tolerance, and improve the quality of life and Chinese symptoms, and the effectiveness is rated as grade A. Adverse reactions are mostly general adverse reactions, and no serious adverse reactions have been reported, consistent with the known risks listed in the instruction for adverse events, contraindications, and precautions. The safety is rated as grade A, and the daily cost is 7.74 yuan. The cost-effectiveness shows that it is a treatment regimen with pharmacoeconomic advantages, and the economic performance is rated as grade A. According to specialist research, Shexiang Tongxin Dropping Pills have good clinical innovation and service innovation, and innovation is rated as grade A. There are no special storage conditions, medicinal material ingredients, or other restrictions, and the clinical use meets the specifications of the medication guidelines. The suitability is rated as grade A. The price level, availability, and affordability of drugs are generally good, and the accessibility is rated as grade A. The clinical value of Shexiang Tongxin Dropping Pills is great.

Download full-text PDF

Source
http://dx.doi.org/10.19540/j.cnki.cjcmm.20231114.502DOI Listing

Publication Analysis

Top Keywords

shexiang tongxin
28
tongxin dropping
28
dropping pills
24
rated grade
24
adverse reactions
12
evaluation shexiang
8
clinical shexiang
8
shexiang
7
tongxin
7
dropping
7

Similar Publications

Acute myocardial infarction (AMI) remains a significant health challenge globally, highlighting the ongoing need for effective treatments. Shexiang-Tongxin dropping pill (STDP) is widely utilized as a therapeutic option for AMI in China and Southeast Asia. However, the intricate mechanisms of action of STDP against AMI remain largely unknown.

View Article and Find Full Text PDF

Background: Microvascular dysfunction (MVD) is common in patients with myocardial infarction receiving reperfusion therapy and is associated with adverse cardiac prognosis. Accumulating evidence suggests a protective role of Shexiang Tongxin dropping pill (STDP) in MVD. However, the specific effects and the underlying mechanisms of STDP in the context of MVD after myocardial ischemia-reperfusion (IR) remains unclear.

View Article and Find Full Text PDF

[Mechanism of Shexiang Tongxin Dropping Pills in treating diabetic cardiomyopathy based on network pharmacology and animal experiments].

Zhongguo Zhong Yao Za Zhi

April 2024

Key Laboratory of Basic Research on Syndromes and Prescriptions, Ministry of Education, Beijing University of Chinese Medicine Beijing 100029, China Beijing Key Laboratory of Basic Research on Symptoms and Prescriptions Beijing 100029, China Research Institute of Chinese Medicine, Beijing University of Chinese Medicine Beijing 100029, China.

This study aimed to explore the mechanism of Shexiang Tongxin Dropping Pills(STDP) in treating diabetic cardiomyopathy(DCM) based on network pharmacology, molecular docking, and animal experiments. BATMAN, TCMSP, and GeneCards were searched for the active ingredients and targets of STDP against DCM. STRING and Cytoscape were used to build the protein-protein interaction(PPI) network and "drug-active ingredient-target" network.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of Shexiang Tongxin dropping pill (STDP) in reducing myocardial injury caused by coronary microembolization (CME) in rat models.
  • Researchers employed various tests such as gene chip analysis, qRT-PCR, and western blot to analyze gene expression, inflammation, and cell viability in cardiomyocytes.
  • Results demonstrated that STDP decreases inflammation and cell apoptosis through the suppression of the APOC1 and STAT3 signaling pathways, suggesting APOC1's significant role in CME-induced myocardial injury.
View Article and Find Full Text PDF

Objective: To study the effect of Shexiang Tongxin Dropping Pill (STDP) on angiogenesis in diabetic cardiomyopathy mice with coronary microcirculation dysfunction (CMD).

Methods: According to a random number table, 6 of 36 SPF male C57BL/6 mice were randomly selected as the control group, and the remaining 30 mice were injected with streptozotocin intraperitoneally to replicate the type 1 diabetes model. Mice successfully copied the diabetes model were randomly divided into the model group, STDP low-dose group [15 mg/(kg·d)], medium-dose group [30 mg/(kg·d)], high-dose group [60 mg/(kg·d)], and nicorandil group [15 mg/(kg·d)], 6 in each group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!